Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2018. Click here for pdf version.

Highlights:

• Revenue up 21% to £8.8 million
• Profit before tax up 19% to £6.9 million
• Cash up £0.8 million to £7.0 million
• Second interim dividend of 36p per share (2017: 31p)
• Special dividend of 55p per share (2017: 40p)

(more…)